




Dayna Leis, AGPCNP, OCN, Doaa Ayoubi, PharmD, Sherril Card-Gordon, MSN, RN, OCN, CCRC, Ankeeta Joshi, Erika Waalkes

Background

Operations at the Clinical Trials Office (CTO) at Perlmutter Cancer Center (PCC) are decentralized over multiple locations with research patients being seen and treated in several buildings. The Investigational Pharmacy (IP) was housed at the PCC's original location on 34th Street, requiring investigational product to be transported same day to participants receiving treatment at other locations, which was logistically challenging and lengthened the wait time for treatment. In 2022, the accrual of participants in treatment trials at the 34th Street location accounted for only 57% of the total Manhattan accrual. The Ambulatory Care Center at 38th Street provided care and treatment for 35% of these accruals and housed four clinical trial disease management groups (DMGs).

Goals



increase # of treatment patients per day

Cancer Center's Journey: Launching a Satellite Investigational Pharmacy

Solutions and Methods

The CTO received approval to establish a satellite IP in the preexisting standard pharmacy space at the cancer center's newest expansion location on 38th Street. A standard operating procedure (SOP) was created outlining the requirements of the satellite IP as well as the terms of the physical movement of investigational product. Key points included licensing, hours of operation, staffing, capacity and scope, software systems, physical equipment such as freezers and hood details, as well as security and access. The SOP also included a detailed moving plan that listed the specific DMGs and specific studies to utilize the new satellite IP, methods of obtaining and documenting sponsor approval for move, supplies and equipment necessary for physical movement of investigational product, and chain of custody documentation and tracking in Vestigo, an online drug accountability system. The plan detailed moving procedures, method, and process of temperature monitoring during transit, as well as documentation and final physical inspection of investigational products upon receipt at the new location.

Outcomes

Patient wait time successfully reduced by an average of 31 minutes

Based on comparison of time from order to administration for 1485 investigational treatment encounters in year prior to 1503 encounters in 11 months since implementation

Establishing an entirely new satellite IP location is a major undertaking that requires detailed planning, organization, and execution

The established process and workflow will be used for future operational expansion and may be utilized as guidance by other institutions

Further evaluation planned to assess impact on key goals of patient satisfaction, staffing, and ability to increase the overall number of patients treated

Perlmutter **Cancer** Center

An NCI-designated Comprehensive Cancer Center

Lessons Learned and Future Directions